Doxorubicin (DOX)-associated cognitive impairment has been attributed to increased levels of peripheral tumor necrosis factor-alpha (TNF-α), which disrupts the integrity of the blood-brain barrier and subsequently stimulates neuroinflammation via interleukin-1, interleukin-6, and nuclear factor kappa beta (Ren et al. 2019; Alsaud et al. 2023). The gene discussed is TNF; the disease is Cognitive impairment.